IL154170A0 - Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects - Google Patents

Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects

Info

Publication number: IL154170A0
Authority: IL; Israel
Prior art keywords: treatment; novel; recombinant; side effects; recombinant erythropoietin
Prior art date: 2000-08-11

Application number

IL15417001A

Other languages

English (en)

Original Assignee

Baxter Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-11

Filing date

2001-08-09

Publication date

2003-07-31

2001-08-09 Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa

2003-07-31 Publication of IL154170A0 publication Critical patent/IL154170A0/xx

Links

108090000394 Erythropoietin Proteins 0.000 title abstract 4
102000003951 Erythropoietin Human genes 0.000 title abstract 4
229940105423 erythropoietin Drugs 0.000 title abstract 4
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 4
230000000694 effects Effects 0.000 title abstract 3
238000002560 therapeutic procedure Methods 0.000 title abstract 2
238000011282 treatment Methods 0.000 abstract 6
206010020772 Hypertension Diseases 0.000 abstract 3
208000007536 Thrombosis Diseases 0.000 abstract 2
230000002411 adverse Effects 0.000 abstract 2
208000007502 anemia Diseases 0.000 abstract 2
108010090921 epoetin omega Proteins 0.000 abstract 2
229950008767 epoetin omega Drugs 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
241000699800 Cricetinae Species 0.000 abstract 1
241000699802 Cricetulus griseus Species 0.000 abstract 1
108010074604 Epoetin Alfa Proteins 0.000 abstract 1
206010028813 Nausea Diseases 0.000 abstract 1
206010047095 Vascular pain Diseases 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 abstract 1
229960003388 epoetin alfa Drugs 0.000 abstract 1
108010002601 epoetin beta Proteins 0.000 abstract 1
229960004579 epoetin beta Drugs 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
210000003292 kidney cell Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000008693 nausea Effects 0.000 abstract 1
210000001672 ovary Anatomy 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Hematology (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

IL15417001A 2000-08-11 2001-08-09 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects IL154170A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/637,962 US7078376B1 (en)	2000-08-11	2000-08-11	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
PCT/EP2001/009209 WO2002014356A2 (fr)	2000-08-11	2001-08-09	Methodes therapeutiques de traitement de sujet avec une erytrhopoietine recombinee presentant une activite elevee et peu d'effets secondaires

Publications (1)

Publication Number	Publication Date
IL154170A0 true IL154170A0 (en)	2003-07-31

Family

ID=24558080

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL15417001A IL154170A0 (en)	2000-08-11	2001-08-09	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
IL154170A IL154170A (en)	2000-08-11	2003-01-29	Medicinal products containing recombinant erythropoietin with high activity and limited side effects
IL197584A IL197584A (en)	2000-08-11	2009-03-12	Medical use of recombinant erythropoietin for the prevention and treatment of chronic heart failure and fatigue @ and related pain @

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL154170A IL154170A (en)	2000-08-11	2003-01-29	Medicinal products containing recombinant erythropoietin with high activity and limited side effects
IL197584A IL197584A (en)	2000-08-11	2009-03-12	Medical use of recombinant erythropoietin for the prevention and treatment of chronic heart failure and fatigue @ and related pain @

Country Status (18)

Country	Link
US (1)	US7078376B1 (fr)
EP (2)	EP1994940B1 (fr)
JP (1)	JP5105687B2 (fr)
KR (2)	KR100885601B1 (fr)
CN (1)	CN100558744C (fr)
AT (2)	ATE555802T1 (fr)
AU (3)	AU2001291755B2 (fr)
BR (1)	BRPI0113189B1 (fr)
CA (2)	CA2804958A1 (fr)
CZ (1)	CZ304572B6 (fr)
DE (1)	DE60131286T2 (fr)
HU (1)	HUP0300740A3 (fr)
IL (3)	IL154170A0 (fr)
MX (1)	MXPA03001237A (fr)
NZ (2)	NZ542370A (fr)
PL (1)	PL364248A1 (fr)
RU (1)	RU2282460C2 (fr)
WO (1)	WO2002014356A2 (fr)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1329119C (fr) *	1988-03-29	1994-05-03	Milton David Goldenberg	Therapie faisant appel a des agents cytotoxiques
US20030232010A2 (en) *	1988-03-29	2003-12-18	Immunomedics, Inc.	Improved cytotoxic therapy
DE10234192B4 (de)	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
US7459436B2 (en) *	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
US7388079B2 (en) *	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
US7141544B2 (en) *	2003-10-10	2006-11-28	Baxter International, Inc.	Stabilization of pharmaceutical protein formulations with small peptides
DE102004063927A1 (de) *	2004-01-23	2005-12-15	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
MXPA06011084A (es) *	2004-03-26	2007-03-21	Johnson & Johnson	Regimen de dosificacion en comunicacion para eritropoyetina.
US20050255112A1 (en) *	2004-05-17	2005-11-17	Lee Jong Y	Compositions and methods for preventing erythropoietin-associated hypertension
US20070037886A1 (en) *	2005-04-26	2007-02-15	Ajinomoto Co., Inc.	Bone marrow erythroid progenitor cell(s) differentiation inducer
US8124095B2 (en)	2005-10-07	2012-02-28	Armagen Technologies, Inc.	Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en)	2005-10-07	2014-06-03	Armagen Technologies, Inc.	Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) *	2005-10-07	2011-11-08	Armagen Technologies, Inc.	Nucleic acids encoding and methods of producing fusion proteins
JP5959795B2 (ja)	2006-08-18	2016-08-02	アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎＴｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ．	血液脳関門送達のための物質
US20080064702A1 (en) *	2006-09-08	2008-03-13	Charalambos Antoniades	Use of folates for the prevention and treatment of vascular diseases
US20090011040A1 (en) *	2007-05-02	2009-01-08	Naash Muna I	Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
RU2344830C1 (ru) *	2007-05-22	2009-01-27	Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава)	Способ определения чувствительности больного с анемией хронических заболеваний к терапии анемического синдрома препаратами рекомбинантного человеческого эритропоэтина
EP2997976A1 (fr)	2007-07-27	2016-03-23	Armagen Technologies, Inc.	Procédés et compositions pour augmenter l'activité alpha-l-iduronidase dans le système nerveux central
AU2008304111B2 (en)	2007-09-27	2014-04-24	Amgen Inc.	Pharmaceutical formulations
EP3381445B1 (fr)	2007-11-15	2023-10-25	Amgen Inc.	Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
US8536123B2 (en) *	2008-01-09	2013-09-17	Health Onvector Inc.	Use of blood flow parameters to monitor or control the dosing of erythropoiesis-stimulating agents
AU2009206306B2 (en)	2008-01-25	2013-06-06	Amgen Inc.	Ferroportin antibodies and methods of use
JP2011519279A (ja)	2008-05-01	2011-07-07	アムジエン・インコーポレーテツド	抗ヘプシジン抗体及び使用の方法
EP2349332B1 (fr)	2008-11-13	2019-10-23	The General Hospital Corporation	Procédés et compositions pour la régulation de l'homéostasie du fer par modulation de la protéine bmp-6
US9533055B2 (en)	2009-03-18	2017-01-03	Armagen Technologies, Inc.	Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
SI2485761T1 (sl)	2009-10-09	2019-05-31	Armagen, Inc.	Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
MX344382B (es)	2009-10-23	2016-12-14	Amgen Inc *	Adaptador de vial y sistema.
ES2545411T5 (es)	2010-06-07	2024-04-05	Amgen Inc	Dispositivo de administración de fármaco
US20120016686A1 (en) *	2010-07-13	2012-01-19	Cerner Innovation, Inc.	Inpatient blood management
ES2388395B1 (es) *	2011-03-18	2013-10-01	Dr Healthcare España, S. L.	Uso de la diaminooxidasa para el tratamiento o la prevención de la fibromialgia o la fatiga crónica.
CA2831100C (fr)	2011-03-31	2020-02-18	Mark Dominis Holt	Adaptateur de flacon et systeme
CA3021845C (fr)	2011-04-20	2022-03-29	Amgen Inc.	Appareil auto-injecteur
LT3045187T (lt)	2011-10-14	2019-07-10	Amgen Inc.	Injekcijų įrenginys ir surinkimo būdas
US8486399B2 (en)	2011-12-02	2013-07-16	Armagen Technologies, Inc.	Methods and compositions for increasing arylsulfatase A activity in the CNS
SI3081249T1 (sl)	2012-11-21	2021-03-31	Amgen Inc.	Naprava za dajanje zdravila
CN105142695B (zh)	2013-03-15	2020-06-02	安进公司	身体轮廓可调适的自动注射器装置
TWI580451B (zh)	2013-03-15	2017-05-01	安美基公司	用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
EP2968503B1 (fr)	2013-03-15	2018-08-15	Intrinsic LifeSciences LLC	Anticorps antihepcidine et leurs utilisations
EP2968775B1 (fr)	2013-03-15	2019-12-18	Amgen Inc.	Boîte à médicament, autoinjecteur et système d'autoinjecteur
SG11201507878SA (en)	2013-03-22	2015-10-29	Amgen Inc	Injector and method of assembly
EP3421066B1 (fr)	2013-10-24	2021-03-03	Amgen Inc.	Injecteur et procédé d'assemblage
EP3060281B1 (fr)	2013-10-24	2019-01-30	Amgen Inc.	Système de distribution de médicaments équipé d'un dispositif de commande sensible à la température
WO2015119906A1 (fr)	2014-02-05	2015-08-13	Amgen Inc.	Système d'administration de médicament doté d'un générateur de champ électromagnétique
JP6640113B2 (ja)	2014-05-07	2020-02-05	アムジエン・インコーポレーテツド	衝撃低減要素を有する自動注入器
CN112237662B (zh)	2014-06-03	2022-10-21	安姆根有限公司	药物递送系统和使用方法
WO2016049036A1 (fr)	2014-09-22	2016-03-31	Intrinsic Lifesciences Llc	Anticorps anti-hepcidine humanisés et utilisations de ceux-ci
WO2016061220A2 (fr)	2014-10-14	2016-04-21	Amgen Inc.	Dispositif d'injection de médicament comportant des témoins visuels et sonores
MA40904A (fr) *	2014-11-03	2017-09-12	Hygeia Tech Inc	Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
EP3848072A1 (fr)	2014-12-19	2021-07-14	Amgen Inc.	Dispositif d'administration de médicament comportant un capteur de proximité
US11357916B2 (en)	2014-12-19	2022-06-14	Amgen Inc.	Drug delivery device with live button or user interface field
US10538589B2 (en)	2015-01-14	2020-01-21	Armagen Inc.	Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2976935C (fr)	2015-02-17	2020-03-10	Amgen Inc.	Dispositif d'administration de medicament a securisation assistee par depression et/ou retour d'informations
WO2016138434A1 (fr)	2015-02-27	2016-09-01	Amgen Inc.	Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
PE20180690A1 (es) *	2015-04-27	2018-04-23	Intercept Pharmaceuticals Inc	Composiciones de acido obeticolico y metodos de uso
WO2017039786A1 (fr)	2015-09-02	2017-03-09	Amgen Inc.	Adaptateur d'ensemble de seringue pour une seringue
ES2755717T3 (es)	2015-12-09	2020-04-23	Amgen Inc	Autoinyector con tapa de señalización
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
US11200298B2 (en)	2016-03-15	2021-12-14	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
WO2017192287A1 (fr)	2016-05-02	2017-11-09	Amgen Inc.	Adaptateur de seringue et guide pour remplir un injecteur sur le corps
EP3455142B1 (fr)	2016-05-13	2023-08-09	Amgen Inc.	Ensemble manchon de flacon
US11238150B2 (en)	2016-05-16	2022-02-01	Amgen Inc.	Data encryption in medical devices with limited computational capability
US11541176B2 (en)	2016-06-03	2023-01-03	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (fr)	2016-07-01	2018-01-04	Amgen Inc.	Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
WO2018034784A1 (fr)	2016-08-17	2018-02-22	Amgen Inc.	Dispositif d'administration de médicament avec détection de positionnement.
US20200261643A1 (en)	2016-10-25	2020-08-20	Amgen Inc.	On-body injector
WO2018136398A1 (fr)	2017-01-17	2018-07-26	Amgen Inc.	Dispositifs d'injection et procédés d'utilisation et d'assemblage associés
US11752258B2 (en)	2017-02-17	2023-09-12	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
US11369736B2 (en)	2017-02-17	2022-06-28	Amgen Inc.	Cannula insertion and retraction mechanisms
CA3050927A1 (fr)	2017-03-06	2018-09-13	Brian Stonecipher	Dispositif d'administration de medicaments dote d'une fonction de prevention d'activation
KR102627069B1 (ko)	2017-03-07	2024-01-18	암겐 인코포레이티드	과압에 의한 바늘 삽입
EP3592404A1 (fr)	2017-03-09	2020-01-15	Amgen Inc.	Mécanisme d'insertion pour dispositif d'administration de médicament
EP3570871B1 (fr)	2017-03-20	2020-11-18	H. Hoffnabb-La Roche Ag	Procédé de glyco-ingénierie in vitro d'une protéine de stimulation de l'érythropoïèse
KR102651078B1 (ko)	2017-03-28	2024-03-22	암겐 인코포레이티드	플런저 로드 및 주사기 조립 시스템 및 방법
US11590294B2 (en)	2017-06-08	2023-02-28	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja)	2017-06-08	2023-01-06	アムジエン・インコーポレーテツド	トルク駆動式薬物送達デバイス
JP7195276B2 (ja)	2017-06-22	2022-12-23	アムジエン・インコーポレーテツド	デバイス起動による衝突／衝撃の低減
MA49461A (fr)	2017-06-23	2020-04-29	Amgen Inc	Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr)	2017-07-14	2020-05-20	Amgen Inc	Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (fr)	2017-07-21	2020-05-27	Amgen Inc.	Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
MA49677A (fr)	2017-07-25	2021-04-21	Amgen Inc	Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
US11484648B2 (en)	2017-07-25	2022-11-01	Amgen Inc.	Drug delivery device with container access system and related method of assembly
MA49838A (fr)	2017-08-09	2020-06-17	Amgen Inc	Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (fr)	2017-08-18	2019-02-21	Amgen Inc.	Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
WO2019070472A1 (fr)	2017-10-04	2019-04-11	Amgen Inc.	Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
CN111132711B (zh)	2017-10-06	2022-07-01	安进公司	带有联锁组件的药物递送装置及相关组装方法
MA50348A (fr)	2017-10-09	2020-08-19	Amgen Inc	Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (fr)	2017-11-03	2019-05-09	Amgen Inc.	Systèmes et approches pour stériliser un dispositif d'administration de médicament
US20200261648A1 (en)	2017-11-06	2020-08-20	Amgen Inc.	Drug delivery device with placement and flow sensing
IL273664B1 (en)	2017-11-06	2026-02-01	Amgen Inc	Full-fledged assemblies and related methods
IL319987A (en)	2017-11-10	2025-06-01	Amgen Inc	Plungers for drug delivery devices
AU2018368338B2 (en)	2017-11-16	2024-07-25	Amgen Inc.	Autoinjector with stall and end point detection
SG11202003004RA (en)	2017-11-16	2020-04-29	Amgen Inc	Door latch mechanism for drug delivery device
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
WO2020023220A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé
WO2020023451A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
CA3103681A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs d'administration pour l'administration de medicaments
EP3829692A1 (fr)	2018-07-31	2021-06-09	Amgen Inc.	Ensemble de trajet de fluide pour dispositif d'administration de médicament
EP3856284A1 (fr)	2018-09-24	2021-08-04	Amgen Inc.	Systèmes et procédés de dosage interventionnel
MA53718A (fr)	2018-09-28	2022-01-05	Amgen Inc	Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
MX2021003492A (es)	2018-10-02	2021-06-18	Amgen Inc	Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
JP7547325B2 (ja)	2018-10-05	2024-09-09	アムジエン・インコーポレーテツド	投薬量インジケータを有する薬物送達デバイス
SG11202103800RA (en)	2018-10-15	2021-05-28	Amgen Inc	Drug delivery device having damping mechanism
AU2019359801B2 (en)	2018-10-15	2025-01-02	Amgen Inc.	Platform assembly process for drug delivery device
MA54057A (fr)	2018-11-01	2022-02-09	Amgen Inc	Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
ES3010833T3 (en)	2018-11-01	2025-04-04	Amgen Inc	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
AU2020263289B2 (en)	2019-04-24	2025-05-22	Amgen Inc.	Syringe sterilization verification assemblies and methods
MX2022002149A (es)	2019-08-23	2022-03-17	Amgen Inc	Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
CU24704B1 (es) *	2019-09-05	2024-04-08	Ct Inmunologia Molecular	Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso
RU2736206C1 (ru) *	2020-02-10	2020-11-12	Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ прогнозирования риска формирования тромбоза постоянного сосудистого доступа в период от 6 месяцев до 1 года у пациентов, находящихся на программном гемодиализе
MX2023013640A (es)	2021-05-21	2023-11-30	Amgen Inc	Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
KR20250099137A (ko)	2022-11-02	2025-07-01	에프. 호프만-라 로슈 아게	당단백질 조성물의 생산 방법
WO2026030152A1 (fr)	2024-07-29	2026-02-05	Amgen Inc.	Système et procédé d'évaluation de la transférabilité d'une recette de remplissage

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR850004274A (ko)	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
DK173067B1 (da) *	1986-06-27	1999-12-13	Univ Washington	Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
CN1224726A (zh) *	1986-06-27	1999-08-04	华盛顿大学评议会	人红血球生成素基因在稳定转染的哺乳动物细胞中的高水平表达
US5661125A (en) *	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions
ZA975264B (en)	1996-06-17	1997-12-17	Smithkline Beecham Corp	Method for treating congestive heart failure.
RU2128517C1 (ru) *	1998-07-20	1999-04-10	Колобков Сергей Леонидович	Стабилизированный водный раствор эритропоэтина
ATE355303T1 (de)	1998-10-23	2006-03-15	Amgen Inc	Methoden und zusammensetzungen zur prävention und behandlung der anämie
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US20020037832A1 (en)	2000-05-02	2002-03-28	Soren Nielsen	Use of alpha-MSH and EPO for preventing or treating ischemic conditions
NZ522851A (en)	2000-05-02	2004-11-26	Action Pharma Aps	Treatment of inflammatory diseases associated with neutrophil or eosinophil granulocyt inflitration with EPO optionally with alpha-MSH
MXPA02011727A (es)	2000-05-26	2003-10-24	Johnson & Johnson	Peptidos neuroprotectores.

2000
- 2000-08-11 US US09/637,962 patent/US7078376B1/en not_active Expired - Lifetime
2001
- 2001-08-09 EP EP07075711A patent/EP1994940B1/fr not_active Expired - Lifetime
- 2001-08-09 CA CA2804958A patent/CA2804958A1/fr not_active Abandoned
- 2001-08-09 NZ NZ542370A patent/NZ542370A/en not_active IP Right Cessation
- 2001-08-09 AT AT07075711T patent/ATE555802T1/de active
- 2001-08-09 IL IL15417001A patent/IL154170A0/xx unknown
- 2001-08-09 AU AU2001291755A patent/AU2001291755B2/en not_active Ceased
- 2001-08-09 DE DE60131286T patent/DE60131286T2/de not_active Expired - Lifetime
- 2001-08-09 NZ NZ524000A patent/NZ524000A/en not_active IP Right Cessation
- 2001-08-09 HU HU0300740A patent/HUP0300740A3/hu unknown
- 2001-08-09 RU RU2003106435/14A patent/RU2282460C2/ru not_active IP Right Cessation
- 2001-08-09 PL PL01364248A patent/PL364248A1/xx not_active IP Right Cessation
- 2001-08-09 KR KR1020087012026A patent/KR100885601B1/ko not_active Expired - Fee Related
- 2001-08-09 AT AT01971896T patent/ATE377426T1/de not_active IP Right Cessation
- 2001-08-09 WO PCT/EP2001/009209 patent/WO2002014356A2/fr not_active Ceased
- 2001-08-09 MX MXPA03001237A patent/MXPA03001237A/es active IP Right Grant
- 2001-08-09 KR KR1020037001938A patent/KR100887463B1/ko not_active Expired - Fee Related
- 2001-08-09 CN CNB018170021A patent/CN100558744C/zh not_active Expired - Fee Related
- 2001-08-09 CA CA2418531A patent/CA2418531C/fr not_active Expired - Fee Related
- 2001-08-09 CZ CZ2003-406A patent/CZ304572B6/cs not_active IP Right Cessation
- 2001-08-09 BR BRPI0113189-3A patent/BRPI0113189B1/pt not_active IP Right Cessation
- 2001-08-09 EP EP01971896A patent/EP1317276B1/fr not_active Expired - Lifetime
- 2001-08-09 AU AU9175501A patent/AU9175501A/xx active Pending
- 2001-08-09 JP JP2002519493A patent/JP5105687B2/ja not_active Expired - Fee Related
2003
- 2003-01-29 IL IL154170A patent/IL154170A/en not_active IP Right Cessation
2006
- 2006-08-17 AU AU2006203640A patent/AU2006203640B2/en not_active Ceased
2009
- 2009-03-12 IL IL197584A patent/IL197584A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP0300740A2 (hu)	2003-09-29
MXPA03001237A (es)	2004-09-10
KR100885601B1 (ko)	2009-02-24
CN100558744C (zh)	2009-11-11
EP1317276A2 (fr)	2003-06-11
JP2004506652A (ja)	2004-03-04
KR100887463B1 (ko)	2009-03-10
RU2282460C2 (ru)	2006-08-27
DE60131286T2 (de)	2008-08-28
CA2418531A1 (fr)	2002-02-21
EP1994940B1 (fr)	2012-05-02
AU2001291755B2 (en)	2006-05-18
KR20030034134A (ko)	2003-05-01
IL154170A (en)	2009-09-22
AU9175501A (en)	2002-02-25
BRPI0113189B1 (pt)	2015-07-07
CZ2003406A3 (cs)	2003-06-18
CA2804958A1 (fr)	2002-02-21
ATE377426T1 (de)	2007-11-15
CN1636014A (zh)	2005-07-06
ATE555802T1 (de)	2012-05-15
AU2006203640B2 (en)	2009-01-08
EP1317276B1 (fr)	2007-11-07
JP5105687B2 (ja)	2012-12-26
IL197584A (en)	2013-07-31
DE60131286D1 (de)	2007-12-20
NZ524000A (en)	2007-06-29
HUP0300740A3 (en)	2010-03-29
PL364248A1 (en)	2004-12-13
IL197584A0 (en)	2011-07-31
BR0113189A (pt)	2003-09-16
US7078376B1 (en)	2006-07-18
CZ304572B6 (cs)	2014-07-16
WO2002014356A3 (fr)	2003-01-30
NZ542370A (en)	2006-09-29
EP1994940A1 (fr)	2008-11-26
AU2006203640A1 (en)	2006-09-14
WO2002014356A2 (fr)	2002-02-21
KR20080048560A (ko)	2008-06-02
CA2418531C (fr)	2013-10-01

Publication	Publication Date	Title
AU9175501A (en)	2002-02-25	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
RU2003106435A (ru)	2004-07-10	Терапевтические способы для лечения субъектов рекомбинантным эритропоэтином, имеющим высокую активность и уменьшенные побочные действия
AU766216B2 (en)	2003-10-09	Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
US20070196375A1 (en)	2007-08-23	Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US8236306B2 (en)	2012-08-07	Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
DE69632062D1 (de)	2004-05-06	Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
AU2001268680A1 (en)	2002-01-02	Methods and compositions for the treatment of peripheral artery disease
SG52443A1 (en)	1998-09-28	Methods and compositions for the treatment of disease with interferon while reducing sid effects
Morreale et al.	2004	Clinical and economic comparison of epoetin alfa and darbepoetin alfa
SI2613798T2 (en)	2018-05-31	Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
JP2009524612A (ja)	2009-07-02	多発性硬化症を治療及び／又は予防するための方法、ならびに多発性硬化症の間欠的治療用及び／又は間欠的予防用の薬剤を製造するためのエリスロポエチンの使用
Berntorp	1996	4 The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP
WO2002058720A3 (fr)	2003-05-15	Dose unitaire de fgf-2 efficace sur le plan angiogenique et methode d'utilisation
Haak et al.	1998	Fenofibrate improves microcirculation in patients with hyperlipidemia
DE69921348D1 (de)	2004-11-25	Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung
CA2843014C (fr)	2020-01-21	Utilisation d'il-12 pour generer de l'erythropoietine endogene
穆淑琪 et al.	1999	Calcinosis cutis following extravasation of calcium gluconate in neonates
Blaser et al.	1989	Intravenous phenytoin: a loading scheme for desired concentrations
Matthews et al.	1987	Iatrogenic superior vena cava syndrome treated with streptokinase
Xu	0	Human Recombinant Erythropoietin Treatment
REIBALDI et al.	1995	on specific growth factors¹.
Poplack	1989	Acute Nonlymphoblastic Leukemia
RU99126728A (ru)	2001-09-20	Способ лечения больных псориазом с неутолимым болевым синдромом
RU97117825A (ru)	1999-07-20	Способ лечения больных эпилепсией